Asthma and Allergy Week at the ATS
We believe it is fitting that the ATS and PAR are inaugurating the “Lung Disease Week” series with asthma and allergy in the spotlight. Asthma is a common inflammatory disease of the airways. Airway inflammation is the central process leading to the defining characteristics, which include recurrent episodes of respiratory symptoms; variable airflow obstruction that is often reversible, either spontaneously or with treatment; and the presence of airway hyper-reactivity.
The American Thoracic Society (ATS) and the Asthma and Allergy Foundation of America (AAFA) support new and more efficacious treatments for asthma and increased funding federal research, education and control.
We welcome Asthma and Allergy Week and our partnership in this awareness campaign, and we look forward to sharing information to help guide patients, advance research, and support clinicians and allied health professionals in their efforts to better control asthma.
Serpil Erzurum, MD
Charlotte Collins, JD
ATS Asthma PARtner — Asthma and Allergy Foundation of America
The Asthma and Allergy Foundation of America (AAFA), a not-for-profit organization founded in 1953, is the leading patient organization for people with asthma and allergies, and the oldest asthma and allergy patient group in the world.
Disclaimer: "The ATS Lung Disease Week Web site is designed for educational purposes only. You should not rely on this information as a substitute for personal medical attention, a diagnosis from a physician, or direct medical care. If you are concerned about your health or that of a family member, please consult your family's healthcare provider immediately. Do not wait for a response from our members, staff or partners."